Vis enkel innførsel

dc.contributor.authorOrstad, Silje
dc.contributor.authorFløtten, Øystein
dc.contributor.authorMadebo, Tesfaye
dc.contributor.authorGulbrandsen, Pål
dc.contributor.authorStrand, Roger
dc.contributor.authorLindemark, Frode
dc.contributor.authorFluge, Sverre
dc.contributor.authorTilseth, Rune Hørgård
dc.contributor.authorSchaufel, Margrethe Aase
dc.date.accessioned2023-12-28T10:19:22Z
dc.date.available2023-12-28T10:19:22Z
dc.date.created2023-10-06T12:44:15Z
dc.date.issued2023
dc.identifier.issn0169-5002
dc.identifier.urihttps://hdl.handle.net/11250/3108984
dc.description.abstractIntroduction The value of shared decision-making and decision aids (DA) has been well documented yet remain difficult to integrate into clinical practice. We wanted to investigate needs and challenges regarding decision-making about advanced lung cancer treatment after first-line therapy, focusing on DA applicability. Methods Qualitative data from separate, semi-structured focus groups with patients/relatives and healthcare professionals were analysed using systematic text condensation. 12 patients with incurable lung cancer, seven relatives, 12 nurses and 18 doctors were recruited from four different hospitals in Norway. Results The participants described the following needs and challenges affecting treatment decisions: 1) Continuity of clinician-patient-relationships as a basic framework for decision-making; 2) barriers to information exchange; 3) negotiation of autonomy; and 4) assessment of uncertainty and how to deal with it. Some clinicians feared DA would steal valuable time and disrupt consultations, arguing that such tools could not incorporate the complexity and uncertainty of decision-making. Patients and relatives reported a need for more information and the possibility both to decline or continue burdensome therapy. Participants welcomed interventions supporting information exchange, like communicative techniques and organizational changes ensuring continuity and more time for dialogue. Doctors called for tools decreasing uncertainty about treatment tolerance and futile therapy. Conclusion Our study suggests it is difficult to develop an applicable DA for advanced lung cancer after first-line therapy that meets the composite requirements of stakeholders. Comprehensive decision support interventions are needed to address organizational structures, communication training including scientific and existential uncertainty, and assessment of frailty and treatment toxicity.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.title“The challenge is the complexity” – A qualitative study about decision-making in advanced lung cancer treatmenten_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2023 The Author(s)en_US
dc.source.articlenumber107312en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.1016/j.lungcan.2023.107312
dc.identifier.cristin2182434
dc.source.journalLung Canceren_US
dc.identifier.citationLung Cancer. 2023, 183, 107312.en_US
dc.source.volume183en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal